By Sneha S K and Sahil Pandey
Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal disorder, the company said on Wednesday.
Shares of the drugmaker were down 48% at $36.41.
The company said the FDA could not arrive at a favorable benefit-risk assessment for the hormone-blocking oral treatment, known as relacorilant, without Corcept providing additional evidence of effectiveness.
The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
"FDA's request for additional data may require additional trials, significantly dimming Corcept's outlook in Cushings," said Truist analyst Joon Lee.
Hypercortisolism, also known as Cushing's syndrome, occurs when the body is exposed to high cortisol activity.
Corcept had submitted trial data that showed that relacorilant made improvements in a wide array of hypercortisolism's signs and symptoms.
"We will meet with the FDA as soon as possible to discuss the best path forward," said Joseph Belanoff, Corcept's CEO.
Main symptoms of hypercortisolism include a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks on the skin. People with Cushing's also experience diabetes, high blood pressure, muscle weakness and immune suppression.
Relacorilant is a selective cortisol modulator designed to block the effects of cortisol, while avoiding certain off‑target hormonal effects.
"Given the company had opportunities to address FDA's concerns during mid and late-stage reviews, it's unclear if any further dialogue can resolve the review issues without additional trials," Lee added.
Corcept is also studying the drug in a variety of serious disorders including ovarian and prostate cancer. Its other drug known as Korlym is approved to treat high blood sugar caused by hypercortisolism in adults with endogenous Cushing's syndrome.
Other approved treatments for Cushing's syndrome include Isturisa by Recordati and Xeris Biopharma's Recorlev.
(Reporting by Sahil Pandey and Sneha S K in Bengaluru; Editing by Shailesh Kuber)
LATEST POSTS
- 1
The most effective method to Oversee Unsold SUVs in the Car Business - 2Orcas seen hunting great white sharks to eat their livers in drone footage recorded in Mexico
- 3Must-Sit in front of the Programs from Europe and the US
- 4Scientists reveal earliest evidence for shifting of Earth’s crust
- 5An Excursion Through Renowned Western Network programs
- Dramatic Dominance d: A Survey of \Feelings in front of an audience\ Theater Play
- Iran war fuels fears of new inflation wave among German consumers
- Which Store is Your Decision ?
- Evidence of lost baptismal rite stage uncovered in Byzantine era cathedral near Sea of Galilee
- Nigeria’s return to Windsor castle signals new era in UK economic partnership
- Consumer outlook on UK economy falls to two-year low
- Flourishing in a Cutthroat Work Market: Vocation Methodologies
- Mali and Canadian miner Barrick agree to resolve tax dispute, ending 2-year standoff
- Scientists discover black hole flare with the light of 10 trillion suns
